Aegerion Pharma (AEGR) Tops Q4 EPS by 32c

Aegerion Pharma (NASDAQ: AEGR) reported Q4 EPS of $0.06, $0.32 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $59.3 million versus the consensus estimate of $52.3 million.

• The Company is now planning to file its Japanese NDA for lomitapide in adult HoFH patients in the fourth quarter of 2015. Based upon the anticipated nine month review period as a result of lomitapide's orphan drug status, the Company continues to plan for a mid-2016 decision.
• Aegerion now expects to initiate a study to evaluate lomitapide in pediatric HoFH patients in the second half of 2015.
• Aegerion recently reached an agreement for formal pricing and reimbursement approval for LOJUXTA® (lomitapide) through The Italian Medicines Agency (AIFA) in line with the Company's original price submitted at the end of 2013 and subject to an annual payment cap. The final decision will be effective upon publication in the official journal, Gazzetta Ufficiali, expected within two months.

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Pan American Silver (PAAS) Misses Q2 EPS by 19c
• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance